?Fig

?Fig.1C].1C]. 23 C for 30 min to obtain peripheral blood mononuclear cells (PBMCs) using Ficoll (Nycomed Pharma AS, Oslo, Norway). Cytotoxicity assay K562 cells were labelled with Calcein-AM (Dojindo Laboratories, Kumamoto, Japan) at 37 C for 30 min. After washing with PBS, 5103 Calcein-AM-labelled K562 cells were added to a 96-well plate with 100 L RPMI-1640 medium (Gibco, Grand Island, NY, USA). PBMCs were added to the wells (S)-Amlodipine at effector-target ratios of 20:1 in 100 L medium. Spontaneous release was obtained by incubating the target cells in medium alone, and maximum release was obtained after treatment with 1% Triton X-100. All experiments were performed in triplicate wells. Cytotoxicity was calculated according to the following formula: [(experimental release – spontaneous release)/(maximum release – spontaneous release)] 100%24. PD-1 detection on cytokine stimulated NK cells PBMCs were incubated with or without interleukin (IL)-2 for 2 days. The cells were then incubated with mouse mAbs against human CD56 (FITC), CD3 (PerCP), and PD-1 (APC). The control groups were stained with isotype-matched antibodies. After one wash with PBS, the cells were detected by the FACSCalibur cell analyzer. The data were analyzed as above. Plasma cytokine analysis Plasma from all participants was measured in duplicate wells using the Milliplex human cytokine/chemokine 96-well plate assay (Millipore, Billerica, MA, USA). The plates were read on a Luminex 200 analyzer (Luminex Corporation, Austin, TX, USA). Five analytes were measured: IL-2, tumor necrosis factor-alpha (TNF-), IL-10, IFN-, and IL-6. Intracellular staining analysis Intracellular staining was carried out according to the manual of the BD Cytofix/Cytoperm? kit (BD Biosciences). Briefly, PBMCs were harvested and adjusted to 1 1 106 cells/mL. The cells were incubated with 0.1% GolgiStop (BD Biosciences) in an incubator for 4 h. The cells were incubated with mouse mAbs against human CD56 (FITC), CD3 (PerCP), and PD-1 (APC). These were followed by intracellular staining with mouse mAbs against human perforin (PE), granzyme B (PE), or IFN- (PE) (BD Pharmingen, San Jose, CA, USA), as well as the isotype control antibodies. After one wash with PBS, the cells were detected by the FACSCalibur cell analyzer. The data were analyzed as above. Degranulation assay As previously explained, the expression of CD107a was used to assess the cytotoxicity ability of NK cells 25, 26. PBMCs and K562 cells were incubated at a ratio of 10:1. A mouse mAb against human CD107a-PE (BD Biosciences) and an isotype control antibody were added to the cells. Following activation with K562 cells for (S)-Amlodipine 1 (S)-Amlodipine h, 0.1% GolgiStop was added. After another 3 h incubation, the cells were collected and stained with mouse mAbs against human CD3 (PerCP), CD56 (FITC), Rabbit Polyclonal to SLC9A3R2 and PD-1 (APC). After one wash with PBS, the cells were detected and analyzed as above. Statistical analysis The proportions of cells were analyzed and compared using the paired = 0.1134; Fig. ?Fig.1C].1C]. The PBMCs from lung malignancy patients and healthy donors were tested for NK cell cytotoxicity. The antitumor function of the lung malignancy NK cells was significantly lower than that of the healthy donors (9.88% 4.66% 15.04% 5.42%, = 0.0071; (S)-Amlodipine Fig. ?Fig.11D). Open in a separate window Physique 1 NK cells in lung malignancy patients demonstrate reduced antitumor function. (A) Representative flow cytometry analysis of the expression levels of CD3-CD56+ NK cells. (B) Graph showing the percentages of NK cells in the blood of lung malignancy patients (LC) and healthy donors (HD). Data were analyzed and compared using the paired 0.01. Lung malignancy patients have high PD-1+ NK cell levels PD-1 is rarely expressed around the NK cells of.